Re-vaccination following Autologous Hematopoietic Stem Cell Transplantation is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance

Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Due to decreased vaccine rates among the general population causing loss of herd...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Biol Blood Marrow Transplant
Autori principali: Palazzo, Meighan, Shah, Gunjan L., Copelan, Olivia, Seier, Kenneth, Devlin, Sean M., Maloy, Molly, Kenny, Sheila, Hassoun, Hani, Korde, Neha S., Lendvai, Nikoletta, Lesokhin, Alexander M., Mailankody, Sham, Chung, David J., Koehne, Guenther, Landgren, C. Ola, Landau, Heather, Giralt, Sergio A., Perales, Miguel-Angel
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6673673/
https://ncbi.nlm.nih.gov/pubmed/29288818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2017.12.795
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi